Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 14.92
(-3.83%)
USD 14.92
(-3.83%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 240.73 Million USD | -1.96% |
| 2022 | 232.81 Million USD | 68.35% |
| 2021 | 138.28 Million USD | 57.16% |
| 2020 | 87.99 Million USD | -47.87% |
| 2019 | 168.79 Million USD | 945.67% |
| 2018 | 16.14 Million USD | -48.6% |
| 2017 | 31.4 Million USD | 19736.49% |
| 2016 | 158.33 Thousand USD | -58.55% |
| 2015 | 382 Thousand USD | 118.29% |
| 2014 | 175 Thousand USD | -39.71% |
| 2013 | 290.26 Thousand USD | 97.63% |
| 2012 | 146.87 Thousand USD | -50.4% |
| 2011 | 296.13 Thousand USD | -52.24% |
| 2010 | 620.09 Thousand USD | -83.57% |
| 2009 | 3.77 Million USD | 189.53% |
| 2008 | 1.3 Million USD | 169.29% |
| 2007 | 483.93 Thousand USD | -18.73% |
| 2006 | 595.45 Thousand USD | 0.81% |
| 2005 | 590.68 Thousand USD | 200.9% |
| 2004 | 196.3 Thousand USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 2179.00 USD | -27.73% |
| 2001 | 3015.00 USD | -86.77% |
| 2000 | 22.78 Thousand USD | -33.27% |
| 1999 | 34.14 Thousand USD | 28.4% |
| 1998 | 26.59 Thousand USD | -32.88% |
| 1997 | 39.61 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -4.78 Million USD | -5.68% |
| 2024 Q1 | -712 Thousand USD | -105.82% |
| 2024 Q2 | -4.52 Million USD | -535.53% |
| 2023 Q1 | 59.85 Million USD | 107.01% |
| 2023 Q2 | 143.59 Million USD | 139.9% |
| 2023 Q4 | 12.23 Million USD | -2.49% |
| 2023 FY | 228.24 Million USD | -1.96% |
| 2023 Q3 | 12.55 Million USD | -91.26% |
| 2022 Q4 | 28.91 Million USD | -3.0% |
| 2022 Q2 | 149.22 Million USD | 500.1% |
| 2022 Q1 | 24.86 Million USD | -35.05% |
| 2022 FY | 232.81 Million USD | 68.35% |
| 2022 Q3 | 29.8 Million USD | -80.02% |
| 2021 Q4 | 38.28 Million USD | -16.58% |
| 2021 FY | 138.28 Million USD | 57.16% |
| 2021 Q1 | 21.3 Million USD | 179.1% |
| 2021 Q2 | 32.81 Million USD | 54.02% |
| 2021 Q3 | 45.89 Million USD | 39.86% |
| 2020 Q3 | 27.37 Million USD | 16.35% |
| 2020 Q4 | 7.63 Million USD | -72.12% |
| 2020 Q2 | 23.52 Million USD | -20.12% |
| 2020 FY | 87.99 Million USD | -47.87% |
| 2020 Q1 | 29.45 Million USD | -31.96% |
| 2019 Q1 | 34.65 Million USD | 207.93% |
| 2019 Q3 | 42.69 Million USD | -11.32% |
| 2019 Q4 | 43.29 Million USD | 1.4% |
| 2019 Q2 | 48.14 Million USD | 38.92% |
| 2019 FY | 168.79 Million USD | 945.67% |
| 2018 Q3 | 727.37 Thousand USD | 11.88% |
| 2018 FY | 16.14 Million USD | -48.6% |
| 2018 Q4 | 11.25 Million USD | 1447.34% |
| 2018 Q2 | 650.12 Thousand USD | -81.48% |
| 2018 Q1 | 3.5 Million USD | -59.72% |
| 2017 Q1 | 4.36 Million USD | 13869.59% |
| 2017 FY | 31.4 Million USD | 19736.49% |
| 2017 Q2 | 8.98 Million USD | 105.84% |
| 2017 Q4 | 8.71 Million USD | -6.73% |
| 2017 Q3 | 9.34 Million USD | 3.97% |
| 2016 Q3 | 39.58 Thousand USD | -9.52% |
| 2016 Q2 | 43.75 Thousand USD | 0.0% |
| 2016 Q4 | 31.25 Thousand USD | -21.05% |
| 2016 FY | 158.33 Thousand USD | -58.55% |
| 2016 Q1 | 43.75 Thousand USD | 0.0% |
| 2015 Q4 | 43.75 Thousand USD | -64.65% |
| 2015 FY | 382 Thousand USD | 118.29% |
| 2015 Q3 | 123.75 Thousand USD | 182.86% |
| 2015 Q2 | 43.75 Thousand USD | -74.38% |
| 2015 Q1 | 170.75 Thousand USD | 290.29% |
| 2014 Q1 | 43.75 Thousand USD | 0.0% |
| 2014 Q4 | 43.75 Thousand USD | 0.0% |
| 2014 Q3 | 43.75 Thousand USD | 0.0% |
| 2014 Q2 | 43.75 Thousand USD | 0.0% |
| 2014 FY | 175 Thousand USD | -39.71% |
| 2013 Q1 | 159.01 Thousand USD | 263.47% |
| 2013 Q2 | 43.75 Thousand USD | -72.49% |
| 2013 Q3 | 43.75 Thousand USD | 0.0% |
| 2013 Q4 | 43.75 Thousand USD | 0.0% |
| 2013 FY | 290.26 Thousand USD | 97.63% |
| 2012 Q1 | -71.59 Million USD | -124.62% |
| 2012 FY | 146.87 Thousand USD | -50.4% |
| 2012 Q4 | 43.75 Thousand USD | -8.7% |
| 2012 Q3 | 47.91 Thousand USD | 53.33% |
| 2012 Q2 | 31.25 Thousand USD | 100.04% |
| 2011 FY | 296.13 Thousand USD | -52.24% |
| 2011 Q1 | 4.99 Million USD | 2664.32% |
| 2011 Q2 | 296.13 Thousand USD | -94.07% |
| 2011 Q3 | - USD | -100.0% |
| 2011 Q4 | 290.84 Million USD | 0.0% |
| 2010 Q3 | 133.99 Thousand USD | -14.84% |
| 2010 Q4 | 180.69 Thousand USD | 34.86% |
| 2010 FY | 620.09 Thousand USD | -83.57% |
| 2010 Q1 | 148.06 Thousand USD | -26.91% |
| 2010 Q2 | 157.34 Thousand USD | 6.27% |
| 2009 FY | 3.77 Million USD | 189.53% |
| 2009 Q4 | 202.58 Thousand USD | -92.31% |
| 2009 Q1 | 701.72 Thousand USD | 174.45% |
| 2009 Q2 | 235.65 Thousand USD | -66.42% |
| 2009 Q3 | 2.63 Million USD | 1017.42% |
| 2008 Q4 | -942.56 Thousand USD | -1362.98% |
| 2008 Q3 | 74.63 Thousand USD | -77.72% |
| 2008 Q2 | 334.94 Thousand USD | 342.73% |
| 2008 Q1 | 75.65 Thousand USD | -62.46% |
| 2008 FY | 1.3 Million USD | 169.29% |
| 2007 Q2 | - USD | -100.0% |
| 2007 Q1 | 11.09 Thousand USD | -71.72% |
| 2007 FY | 483.93 Thousand USD | -18.73% |
| 2007 Q4 | 201.54 Thousand USD | -26.71% |
| 2007 Q3 | 274.99 Thousand USD | 0.0% |
| 2006 FY | 595.45 Thousand USD | 0.81% |
| 2006 Q3 | 246.22 Thousand USD | 328.22% |
| 2006 Q1 | 252.5 Thousand USD | 20.08% |
| 2006 Q2 | 57.5 Thousand USD | -77.23% |
| 2006 Q4 | 39.22 Thousand USD | -84.07% |
| 2005 Q3 | 173.3 Thousand USD | 123.29% |
| 2005 Q2 | 77.61 Thousand USD | -40.06% |
| 2005 Q1 | 129.49 Thousand USD | -18.61% |
| 2005 FY | 590.68 Thousand USD | 200.9% |
| 2005 Q4 | 210.27 Thousand USD | 21.33% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | 159.1 Thousand USD | 327.7% |
| 2004 Q1 | - USD | 100.0% |
| 2004 FY | 196.3 Thousand USD | 0.0% |
| 2004 Q3 | 37.2 Thousand USD | 0.0% |
| 2003 Q3 | 198.00 USD | -76.81% |
| 2003 Q1 | 1518.00 USD | 1665.12% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | -2732.00 USD | -1479.8% |
| 2003 Q2 | 854.00 USD | -43.74% |
| 2002 Q1 | 1292.00 USD | 124.65% |
| 2002 FY | 2179.00 USD | -27.73% |
| 2002 Q4 | 86.00 USD | -67.05% |
| 2002 Q3 | 261.00 USD | -51.67% |
| 2002 Q2 | 540.00 USD | -58.2% |
| 2001 Q4 | -5241.00 USD | -266.54% |
| 2001 FY | 3015.00 USD | -86.77% |
| 2001 Q2 | 89.00 USD | -98.23% |
| 2001 Q1 | 5020.00 USD | -28.92% |
| 2001 Q3 | 3147.00 USD | 3435.96% |
| 2000 Q1 | 4751.00 USD | -76.25% |
| 2000 FY | 22.78 Thousand USD | -33.27% |
| 2000 Q4 | 7062.00 USD | 52.96% |
| 2000 Q2 | 6354.00 USD | 33.74% |
| 2000 Q3 | 4617.00 USD | -27.34% |
| 1999 Q3 | 10 Thousand USD | 0.0% |
| 1999 FY | 34.14 Thousand USD | 28.4% |
| 1999 Q2 | 10 Thousand USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | 20 Thousand USD | 100.0% |
| 1998 Q2 | 10 Thousand USD | 0.0% |
| 1998 FY | 26.59 Thousand USD | -32.88% |
| 1998 Q3 | - USD | -100.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 FY | 39.61 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | -77.968% |
| Codexis, Inc. | 57.33 Million USD | -319.882% |
| Viridian Therapeutics, Inc. | -1 Million USD | 23982.44% |
| Organovo Holdings, Inc. | -5.38 Million USD | 4567.155% |